Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:80525 |
Name | differentiated high-grade thyroid carcinoma |
Definition | A thyroid gland adenocarcinoma characterized by extensive evidence of follicular cell differentiation. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer endocrine gland cancer thyroid cancer thyroid gland carcinoma thyroid gland adenocarcinoma differentiated high-grade thyroid carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
NRAS mutant | Pazopanib + Trametinib | differentiated high-grade thyroid carcinoma | predicted - sensitive | detail... |
RET fusion | Selpercatinib | differentiated high-grade thyroid carcinoma | sensitive | detail... |
RET fusion | Pralsetinib | differentiated high-grade thyroid carcinoma | sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03475953 | Phase Ib/II | Avelumab + Regorafenib | A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors (REGOMUNE) | Recruiting | FRA | 0 |
NCT03732495 | Phase II | Denosumab + Lenvatinib | Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas (LENVOS) | Unknown status | FRA | 0 |
NCT03753919 | Phase II | Durvalumab + Tremelimumab | Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial (DUTHY) | Terminated | ESP | 0 |
NCT04514484 | Phase I | Cabozantinib + Nivolumab | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | Active, not recruiting | USA | 0 |
NCT04544111 | Phase II | Dabrafenib + Spartalizumab Spartalizumab + Trametinib | PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer | Active, not recruiting | USA | 0 |
NCT05783323 | Phase II | Larotrectinib | Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer | Recruiting | USA | 0 |
NCT06007924 | Phase II | Defactinib + RO5126766 | A Study of Avutometinib and Defactinib in People With Thyroid Cancer | Recruiting | USA | 0 |
NCT06235216 | Phase II | Sacituzumab govitecan-hziy | Sacituzumab govitEcan in THYroid Cancers (SETHY) | Recruiting | ESP | 0 |